Nothing Special   »   [go: up one dir, main page]

CN106831731B - A kind of synthetic method of Selinexor bulk pharmaceutical chemicals - Google Patents

A kind of synthetic method of Selinexor bulk pharmaceutical chemicals Download PDF

Info

Publication number
CN106831731B
CN106831731B CN201710031845.0A CN201710031845A CN106831731B CN 106831731 B CN106831731 B CN 106831731B CN 201710031845 A CN201710031845 A CN 201710031845A CN 106831731 B CN106831731 B CN 106831731B
Authority
CN
China
Prior art keywords
compound
added
reaction
stirring
organic phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201710031845.0A
Other languages
Chinese (zh)
Other versions
CN106831731A (en
Inventor
陈新颖
徐亮
刘文忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Hao Hao Biological Technology Co Ltd
Original Assignee
Guangzhou Hao Hao Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Hao Hao Biological Technology Co Ltd filed Critical Guangzhou Hao Hao Biological Technology Co Ltd
Priority to CN201710031845.0A priority Critical patent/CN106831731B/en
Publication of CN106831731A publication Critical patent/CN106831731A/en
Application granted granted Critical
Publication of CN106831731B publication Critical patent/CN106831731B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a kind of synthetic methods of Selinexor bulk pharmaceutical chemicals, comprising the following steps: mixes compound 6, methylene chloride and ethyl acetate, compound 4, T are added at low temperature3P and DIPEA is added water after reaction and ethyl acetate, liquid separation, organic phase is evaporated to obtain 7 crude product of compound;Compound 7, glacial acetic acid and sodium iodide are mixed, heated up, reaction;After reaction, water and methylene chloride is added in cooling, is washed through stratification, organic phase, is distilled after dry and is obtained compound 8;After compound 1, DBACO, DMF are mixed, the DMF solution of compound 8, reaction is added dropwise;After completion of the reaction, water is added and ethyl acetate, organic phase are recrystallized to give compound 5 after is evaporated.Synthetic method of the invention overcomes the problem of traditional synthesis technology is easy to produce trans- impurity, reduces synthesis step, improves yield, provides a kind of new technique for the synthesis of Selinexor bulk pharmaceutical chemicals.

Description

A kind of synthetic method of Selinexor bulk pharmaceutical chemicals
Technical field
The present invention relates to biomedicine technical fields, particularly, are related to a kind of synthetic method of Selinexor bulk pharmaceutical chemicals.
Background technique
Selinexor is a kind of oral bio effective as selective core output protein inhibitor, first enters within 2012 and faces Bed, has carried out 21 clinical tests altogether so far, and indication includes chronic myelogenous leukemia, acute myeloid leukaemia, acute Lymphocytic leukemia, prostate cancer, melanoma, non-small cell lung cancer, glioma, at neuroblastoma, gynecological tumor, more Unrestrained property large B cell lymphoid tumor, squamous cell carcinoma, carcinoma of the rectum etc..In May, 2014, it is acute myelogenous that FDA authorizes Selinexor treatment The Orphan drug title of leukaemia and diffusivity large B cell lymphoid tumor, in June, 2014, EMA are equally granted by Selinexor treatment The Orphan drug title of both diseases.It obtains FDA and treats the identification of Huppert's disease Orphan drug in January, 2015.
Currently, the synthesis technology having disclosed, reaction equation are as follows:
Wherein, compound 5 is Selinexor bulk pharmaceutical chemicals.
But in this method, it is easy to overturn from 1 to 2 double bond of intermediate, trans- impurity is easy to produce when being synthetically produced, Compare it is difficult remove, influence yield;In intermediate 3 and 4 synthesis material medicine 5 of intermediate, ultralow temperature is needed, and product needed column Purifying, yield is only 20%.
Summary of the invention
It is an object of that present invention to provide a kind of synthetic methods of Selinexor raw material drug compound 5, are asked with solution technology Topic.
A kind of synthetic method of Selinexor bulk pharmaceutical chemicals, comprising the following steps:
A, the synthesis of compound 7
Compound 6, methylene chloride and ethyl acetate are mixed, after stirring and dissolving, compound 4, T are added at low temperature3P (n-propyl phosphoric anhydride) and DIPEA (n,N-diisopropylethylamine);Low temperature 25-35min is reacted, to the end of reacting Methylene chloride is added afterwards and water, liquid separation, organic phase are evaporated to obtain 7 crude product of compound, crude product does not purify directly to be thrown down;
B, the synthesis of compound 8
Compound 7 obtained by upper step, glacial acetic acid and sodium iodide are mixed, are warming up to 110-120 DEG C, reacts 2.5-3.5h;Instead After answering, system is down to room temperature, and water and methylene chloride is added, after stirring 8-15min, stratification, and organic phase saturated carbon Sour hydrogen sodium and saturated sodium-chloride washing, distillation obtains 8 crude product of compound after anhydrous sodium sulfate is dry, is dissolved in DMF (fumaric acid diformazan Ester) in, obtain the DMF solution of compound 8;
C, the synthesis of compound 5
After compound 1, DBACO (triethylene diamine), DMF are mixed, after stirring and dissolving, it is added dropwise to reaction system and walks institute The DMF solution for obtaining compound 8 after being added dropwise, continues stirring 3-4 hours;After completion of the reaction, water and acetic acid are added into system Ethyl ester, organic phase is evaporated rear ethyl acetate and petroleum ether is recrystallized to give compound 5.
Preferably, in the step A, the low temperature is 0-2 DEG C.
Preferably, in the DMF solution in the step B, the concentration of 8 crude product of compound is lower than 1%.
The synthetic method of Selinexor bulk pharmaceutical chemicals of the invention, chemical equation are as follows:
The invention has the following advantages: the synthetic method of Selinexor bulk pharmaceutical chemicals of the invention, overcomes traditional In synthesis technology, it is easy to produce trans- impurity, it is more difficult to remove, it influences yield and needs ultralow temperature, and product needed Column purification, the low-down problem of yield, reduces synthesis step, improves yield, and the synthesis for Selinexor bulk pharmaceutical chemicals provides A kind of new technique.
Other than objects, features and advantages described above, there are also other objects, features and advantages by the present invention. The present invention is further detailed explanation below.
Specific embodiment
The embodiment of the present invention is described in detail below, but the present invention can be limited and be covered according to claim Multitude of different ways implement.
Embodiment 1
A kind of synthetic method of Selinexor bulk pharmaceutical chemicals, comprising the following steps:
A, the synthesis of compound 7
In the there-necked flask of 50ml, it is added 0.2g compound 6,15ml methylene chloride and 15ml ethyl acetate, after stirring and dissolving, 0.3g compound 4 and 3gT are added at 0 DEG C3P,0.75gDIPEA;System is reacted in 0 DEG C of stirring 30min, wait react knot 50ml methylene chloride and 30ml water, liquid separation are added after beam, organic phase is evaporated to obtain 7 crude product of compound, and crude product does not purify directly past Lower throwing;
B, the synthesis of compound 8
In the there-necked flask of 50ml, step gained compound 7,40ml glacial acetic acid and 1.38g sodium iodide, are warming up to 115 in addition DEG C, react 3h;After reaction, system is down to room temperature, and system is transferred in 500ml bottles, and 50ml water and 100ml dichloromethane is added Alkane, after stirring 10min, stratification, organic phase is washed with saturated sodium bicarbonate and saturated sodium-chloride, after anhydrous sodium sulfate is dry Distillation obtains 8 crude product of compound, is dissolved in 10mL DMF, obtains the DMF solution of compound 8;
C, the synthesis of compound 5
0.2g compound 1,0.24gDBACO, 20mlDMF are added in 50ml there-necked flask, after stirring and dissolving, to reaction system The DMF solution of step gained compound 8, after being added dropwise, continues stirring 3.5 hours in dropwise addition;After completion of the reaction, add into system Enter 20ml water and 50ml ethyl acetate, organic phase is evaporated rear ethyl acetate and petroleum ether is recrystallized to give 0.158g compound 5, receives Rate 50.9%.
Embodiment 2
A kind of synthetic method of Selinexor bulk pharmaceutical chemicals, comprising the following steps:
A, the synthesis of compound 7
In the there-necked flask of 50ml, it is added 0.2g compound 6,15ml methylene chloride and 15ml ethyl acetate, after stirring and dissolving, 0.3g compound 4 and 3gT are added at 1 DEG C3P,0.75gDIPEA;System is reacted in 1 DEG C of stirring 35min, wait react knot 50ml methylene chloride and 30ml water, liquid separation are added after beam, organic phase is evaporated to obtain 7 crude product of compound, and crude product does not purify directly past Lower throwing;
B, the synthesis of compound 8
In the there-necked flask of 50ml, step gained compound 7,40ml glacial acetic acid and 1.38g sodium iodide, are warming up to 120 in addition DEG C, react 2.5h;After reaction, system is down to room temperature, and system is transferred in 500ml bottles, and 60ml water and 120ml dichloro is added Methane, after stirring 15min, stratification, organic phase is washed with saturated sodium bicarbonate and saturated sodium-chloride, and anhydrous sodium sulfate is dry Distillation obtains 8 crude product of compound afterwards, is dissolved in 12mLDMF, obtains the DMF solution of compound 8;
C, the synthesis of compound 5
0.2g compound 1,0.24gDBACO, 20mlDMF are added in 50ml there-necked flask, after stirring and dissolving, to reaction system The DMF solution of step gained compound 8, after being added dropwise, continues stirring 3 hours in dropwise addition;After completion of the reaction, it is added into system 25ml water and 50ml ethyl acetate, organic phase is evaporated rear ethyl acetate and petroleum ether is recrystallized to give 0.152g compound 5, yield 49.0%.
Embodiment 3
A kind of synthetic method of Selinexor bulk pharmaceutical chemicals, comprising the following steps:
A, the synthesis of compound 7
In the there-necked flask of 50ml, it is added 0.2g compound 6,15ml methylene chloride and 15ml ethyl acetate, after stirring and dissolving, 0.3g compound 4 and 3gT are added at 2 DEG C3P,0.75gDIPEA;System is reacted in 0 DEG C of stirring 25min, wait react knot 40ml methylene chloride and 35ml water, liquid separation are added after beam, organic phase is evaporated to obtain 7 crude product of compound, and crude product does not purify directly past Lower throwing;
B, the synthesis of compound 8
In the there-necked flask of 50ml, step gained compound 7,35ml glacial acetic acid and 1.38g sodium iodide, are warming up to 110 in addition DEG C, react 3.5h;After reaction, system is down to room temperature, and system is transferred in 500ml bottles, and 50ml water and 100ml dichloro is added Methane, after stirring 8min, stratification, organic phase is washed with saturated sodium bicarbonate and saturated sodium-chloride, and anhydrous sodium sulfate is dry Distillation obtains 8 crude product of compound afterwards, is dissolved in 10mL DMF, obtains the DMF solution of compound 8;
C, the synthesis of compound 5
0.2g compound 1,0.24gDBACO, 20mlDMF are added in 50ml there-necked flask, after stirring and dissolving, to reaction system The DMF solution of step gained compound 8, after being added dropwise, continues stirring 4 hours in dropwise addition;After completion of the reaction, it is added into system 20ml water and 40ml ethyl acetate, organic phase is evaporated rear ethyl acetate and petroleum ether is recrystallized to give 0.155g compound 5, yield 49.9%.
The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention, for the skill of this field For art personnel, the invention may be variously modified and varied.All within the spirits and principles of the present invention, made any to repair Change, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.

Claims (3)

1. a kind of synthetic method of Selinexor bulk pharmaceutical chemicals, which is characterized in that its chemical equation is as follows:
The following steps are included:
A, the synthesis of compound 7
Compound 6, methylene chloride and ethyl acetate are mixed, after stirring and dissolving, compound 4, T are added at 0-2 DEG C3P and DIPEA;Stirring 25-35min is reacted, to which methylene chloride and water, liquid separation, being evaporated of organic phase are added after reaction 7 crude product of object is closed, crude product does not purify directly to be thrown down;
B, the synthesis of compound 8
Compound 7 obtained by upper step, glacial acetic acid and sodium iodide are mixed, are warming up to 110-115 DEG C, reacts 2.5-3.5h;Reaction knot Shu Hou, system are down to room temperature, and water and methylene chloride is added, after stirring 8-15min, stratification, and organic phase unsaturated carbonate hydrogen Sodium and saturated sodium-chloride washing, distillation obtains 8 crude product of compound after anhydrous sodium sulfate is dry, is dissolved in DMF, obtains compound 8 DMF solution;
C, the synthesis of compound 5
After compound 1, DBACO, DMF are mixed, after stirring and dissolving, the DMF that step gained compound 8 is added dropwise to reaction system is molten Liquid after being added dropwise, continues stirring 3-4 hours;After completion of the reaction, water is added into system and ethyl acetate, organic phase is evaporated Ethyl acetate and petroleum ether are recrystallized to give compound 5 afterwards.
2. the synthetic method of Selinexor bulk pharmaceutical chemicals as described in claim 1, which is characterized in that in the step B In DMF solution, the concentration of 8 crude product of compound is lower than 1%.
3. the synthetic method of Selinexor bulk pharmaceutical chemicals as described in claim 1, which comprises the following steps:
A, the synthesis of compound 7
In the there-necked flask of 50ml, it is added 0.2g compound 6,15ml methylene chloride and 15ml ethyl acetate, after stirring and dissolving, 0 0.3g compound 4 and 3gT are added at DEG C3P,0.75gDIPEA;System is reacted in 0 DEG C of stirring 30min, to after reaction 50ml methylene chloride is added and 30ml water, liquid separation, organic phase are evaporated to obtain 7 crude product of compound, crude product does not purify directly to be thrown down;
B, the synthesis of compound 8
In the there-necked flask of 50ml, step gained compound 7,40ml glacial acetic acid and 1.38g sodium iodide, are warming up to 115 DEG C, instead in addition Answer 3h;After reaction, system is down to room temperature, and system is transferred in 500ml bottles, and 50ml water and 100ml methylene chloride is added, stirs After mixing 10min, stratification, organic phase is washed with saturated sodium bicarbonate and saturated sodium-chloride, is distilled after anhydrous sodium sulfate is dry 8 crude product of compound is obtained, is dissolved in 10mL DMF, the DMF solution of compound 8 is obtained;
C, the synthesis of compound 5
0.2g compound 1,0.24gDBACO, 20mlDMF are added in 50ml there-necked flask, after stirring and dissolving, is added dropwise to reaction system The DMF solution of compound 8 obtained by upper step after being added dropwise, continues stirring 3.5 hours;After completion of the reaction, it is added into system 20ml water and 50ml ethyl acetate, organic phase is evaporated rear ethyl acetate and petroleum ether is recrystallized to give compound 5.
CN201710031845.0A 2017-01-17 2017-01-17 A kind of synthetic method of Selinexor bulk pharmaceutical chemicals Expired - Fee Related CN106831731B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710031845.0A CN106831731B (en) 2017-01-17 2017-01-17 A kind of synthetic method of Selinexor bulk pharmaceutical chemicals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710031845.0A CN106831731B (en) 2017-01-17 2017-01-17 A kind of synthetic method of Selinexor bulk pharmaceutical chemicals

Publications (2)

Publication Number Publication Date
CN106831731A CN106831731A (en) 2017-06-13
CN106831731B true CN106831731B (en) 2019-11-08

Family

ID=59123134

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710031845.0A Expired - Fee Related CN106831731B (en) 2017-01-17 2017-01-17 A kind of synthetic method of Selinexor bulk pharmaceutical chemicals

Country Status (1)

Country Link
CN (1) CN106831731B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020198606A1 (en) * 2019-03-27 2020-10-01 Karyopharm Therapeutics Inc. Biomarkers for selinexor
CN116514773A (en) * 2023-04-24 2023-08-01 重庆汉佩生物科技有限公司 Verdinexor (KPT-335) and synthesis method of hydrochloride thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842340A (en) * 2011-07-29 2014-06-04 卡尔约药物治疗公司 Nuclear transport modulators and uses thereof
CN103874690A (en) * 2011-07-29 2014-06-18 卡尔约药物治疗公司 Hydrazide containing nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
CN107072992A (en) * 2014-08-15 2017-08-18 卡尔约药物治疗公司 Sai Lingkesi polymorph

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842340A (en) * 2011-07-29 2014-06-04 卡尔约药物治疗公司 Nuclear transport modulators and uses thereof
CN103874690A (en) * 2011-07-29 2014-06-18 卡尔约药物治疗公司 Hydrazide containing nuclear transport modulators and uses thereof
CN106083827A (en) * 2011-07-29 2016-11-09 卡尔约药物治疗公司 Core transport regulator containing hydrazides and application thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
CN107072992A (en) * 2014-08-15 2017-08-18 卡尔约药物治疗公司 Sai Lingkesi polymorph

Also Published As

Publication number Publication date
CN106831731A (en) 2017-06-13

Similar Documents

Publication Publication Date Title
CN106831731B (en) A kind of synthetic method of Selinexor bulk pharmaceutical chemicals
CN106243031B (en) A kind of Ah handkerchief replaces the preparation method of Buddhist nun
CN106632271A (en) Erlotinib derivative with antitumor activity, and preparation method and application thereof
CN107311875A (en) The synthetic method of aramine
CN104974072A (en) Preparation method of silodosin intermediate
CN105884698B (en) A kind of synthetic method of diphenyl substituted quinazoline compounds
CN103910671B (en) Vismodegib and the preparation method of intermediate thereof
CN106632267A (en) Method for synthesizing voriconazole
CN103183716B (en) Preparation method of tauro ursodesoxy cholic acid
CN108558692A (en) A kind of preparation method of amides compound
CN104803978B (en) A kind of preparation method of esomeprazole magnesium
CN103936631A (en) Oximido diphenyl urea compound as well as preparation method and application thereof
CN106977543A (en) The preparation technology of improved Suo Feibuwei intermediates
KR102104957B1 (en) Manufacturing method of copanriship
CN104592230B (en) 2-(granatane3-amino)-4-tetrahydronaphthalene indazole-substituted benzamide compound and application thereof
CN106995478A (en) A kind of synthetic method of the keto lithcholic acid of intermediate 7 of urso
CN102911125A (en) Method for preparing gefitinib intermediate
CN106279114B (en) A kind of synthetic method of Taladegib
CN109678792A (en) A kind of preparation method of stable isotope labeling Pyridostigmine Bromide internal standard reagent
CN105753834B (en) A kind of synthetic method of rosuvastain calcium key chiral intermediate
CN106966937A (en) Diaryl selenide analog derivative and preparation method thereof
CN107573294A (en) The synthetic method of 5 methyl 2 (base of 1,2,3 triazoles of 2H 2) benzoic acid
Wang et al. Liquid-phase parallel synthesis of 2-aryl-5-methoxylcarbonyl-dihydropyrones using soluble polymer support
CN109422681A (en) A kind of preparation method of Pitavastatin Calcium intermediate
CN101759625A (en) Method for synthesizing sutent intermediate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191108

Termination date: 20220117

CF01 Termination of patent right due to non-payment of annual fee